<DOC>
	<DOC>NCT01355614</DOC>
	<brief_summary>This study will assess the safety and efficacy of QAX576 if patients with fistulizing Crohn's disease.</brief_summary>
	<brief_title>A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>At least one draining enterocutaneous perianal fistula Diagnosis of Crohn's disease (CD) must have been established for at least 6 months At least one ineffective fistula treatment (but no previously failed antiTNFα (tumour necrosis factor) antibody treatment) Patients should not suffer from any other health problems that may jeopardize their participation in the study. Current or recent (within 30 days of enrollment, or 5 halflives of the compound, whichever is longer) use of antiTNFα antibody treatment Active Crohn's disease Recent or pending abdominal or anorectal surgery, particularly presence of stricture, or abscess, or retention for which surgery might be indicated Previously failed antiTNFα antibody treatment Intercurrent bacterial or viral (intestinal) infection (serologically or microbiologically confirmed) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>Fistula</keyword>
</DOC>